Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Enalapril maleate
Drug ID BADD_D00767
Description Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypertensive agent that suppresses the renin-angiotensin-aldosterone system to lower blood pressure. It was developed from a targeted research programmed using molecular modelling.[A18459] Being a prodrug, enalapril is rapidly biotransformed into its active metabolite, [enalaprilat], which is responsible for the pharmacological actions of enalapril. The active metabolite of enalapril competitively inhibits the ACE to hinder the production of angiotensin II, a key component of the renin-angiotensin-aldosterone system that promotes vasoconstriction and renal reabsorption of sodium ions in the kidneys. Ultimately, enalaprilat works to reduce blood pressure and blood fluid volume. Commonly marketed under the trade name Vasotec, enalapril was first approved by the FDA in 1985 for the management of hypertension, heart failure, and asymptomatic left ventricular dysfunction. It is also found in a combination product containing [hydrochlorothiazide] that is used for the management of hypertension. The active metabolite enalaprilat is also available in oral tablets and intravenous formulations for injection.
Indications and Usage For the treatment of essential or renovascular hypertension and symptomatic congestive heart failure. It may be used alone or in combination with thiazide diuretics.
Marketing Status Prescription; Discontinued
ATC Code C09AA02
DrugBank ID DB00584
KEGG ID D00621
MeSH ID D004656
PubChem ID 5388961
TTD Drug ID D00SEB
NDC Product Code 0904-5611; 61919-690; 70934-702; 70934-713; 69043-033; 60429-186; 70518-2348; 0904-5609; 51672-4040; 72189-151; 71205-074; 70934-492; 70518-1664; 60760-777; 72789-031; 50090-5292; 23155-704; 67296-0756; 61919-813; 68788-7967; 51672-4038; 50090-0692; 55289-984; 69043-034; 71335-1854; 68788-7671; 55289-591; 0904-5610; 53808-1108; 64679-926; 71335-1427; 23155-772; 51655-341; 68071-2430; 51672-4037; 70518-2445; 71335-0478; 68071-3303; 64679-923; 60760-587; 50090-0690; 64220-143; 70518-0028; 16714-443; 68645-455; 35356-871; 23155-773; 63629-7895; 50090-4560; 31722-020; 70518-2621; 71335-0055; 60429-185; 70934-526; 68682-710; 17404-0009; 69452-237; 68682-712; 63629-1525; 63187-977; 68788-7309; 50090-3275; 64679-924; 68682-711; 23155-705; 68071-1936; 71052-103; 38779-0514; 49452-2706; 0187-0140; 68645-456; 63629-1522; 60429-183; 16714-445; 68071-2670; 68071-2618; 45865-404; 68071-3067; 70518-1564; 16714-444; 68071-3245; 51927-3336; 55111-008; 69043-035; 63629-1526; 61919-277; 51672-4039; 71335-0305; 64679-925; 68788-7275; 0187-0142; 53296-0035; 71205-075; 63187-397; 0904-5502; 70518-1190; 61919-372; 60429-184; 69043-032; 68788-7244; 70934-566; 70934-689; 16714-442; 71335-1910; 0187-0143; 70518-0045; 50090-3378; 68645-457; 0187-0141; 68682-713; 68788-8096; 60760-226; 60760-392; 52652-4001; 72189-282; 58032-0125; 55289-694; 68071-3173; 68788-8061; 51552-0944; 62991-2769
Synonyms Enalapril | MK-421 | MK 421 | MK421 | Renitec | Renitek | Enalapril Maleate | Maleate, Enalapril
Chemical Information
Molecular Formula C24H32N2O9
CAS Registry Number 76420-75-2
SMILES CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CCCC2C(=O)O.C(=CC(=O)O)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Blood pressure decreasedAngiotensin-converting enzymeP12821T82577Not Available
CoughB2 bradykinin receptorP30411T23714Not Available
HepatotoxicityCytochrome P450 3A4P08684T37848Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anxiety disorder19.06.01.002--Not Available
Serositis08.01.05.006--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Epidermal necrosis23.03.03.035--Not Available
Urine output increased13.13.03.002--Not Available
Antinuclear antibody positive13.06.01.003--Not Available
Hepatic enzyme increased13.03.01.019--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Infarction24.04.02.017--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Renal impairment20.01.03.010--Not Available
Sinus disorder22.04.06.002--
Respiratory tract infection22.07.07.001; 11.01.08.017--Not Available
Bone marrow failure01.03.03.005--
Regurgitation07.01.07.004--Not Available
Oropharyngeal discomfort22.02.05.027; 07.05.05.008--Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.004--
The 7th Page    First    Pre   7    Total 7 Pages